Equities analysts forecast that Strongbridge Biopharma plc (NASDAQ:SBBP) will announce earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Strongbridge Biopharma’s earnings, with estimates ranging from ($0.35) to ($0.25). Strongbridge Biopharma reported earnings of ($0.25) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 24%. The firm is expected to report its next quarterly earnings report on Monday, March 26th.

On average, analysts expect that Strongbridge Biopharma will report full-year earnings of ($2.86) per share for the current financial year, with EPS estimates ranging from ($2.87) to ($2.84). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.49) to ($0.82). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Strongbridge Biopharma.

Get Strongbridge Biopharma alerts:

Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.07.

Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald set a $14.00 price target on Strongbridge Biopharma and gave the company a “buy” rating in a research note on Wednesday, January 17th. BidaskClub raised Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research note on Thursday, January 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $12.81.

Shares of Strongbridge Biopharma (NASDAQ:SBBP) traded up $0.17 on Wednesday, hitting $6.82. The stock had a trading volume of 87,737 shares, compared to its average volume of 360,409. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma has a twelve month low of $2.10 and a twelve month high of $9.02. The firm has a market capitalization of $267.05, a price-to-earnings ratio of -2.01 and a beta of 1.98.

A number of large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers acquired a new position in Strongbridge Biopharma in the second quarter valued at about $154,000. California State Teachers Retirement System bought a new position in Strongbridge Biopharma in the second quarter valued at approximately $277,000. Teachers Advisors LLC bought a new position in Strongbridge Biopharma in the second quarter valued at approximately $297,000. Bank of New York Mellon Corp bought a new position in Strongbridge Biopharma in the second quarter valued at approximately $331,000. Finally, Schwab Charles Investment Management Inc. bought a new position in Strongbridge Biopharma in the second quarter valued at approximately $332,000. 57.03% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Strongbridge Biopharma plc (SBBP) Expected to Announce Earnings of -$0.31 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/07/strongbridge-biopharma-plc-sbbp-expected-to-announce-earnings-of-0-31-per-share.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.